Cyclerion Therapeutics, Inc.
CYCN · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 840.9% | 14.8% | -95.5% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 100% | 100% | 100% | 100% |
| EBITDA | -$0 | -$0 | -$0 | $0 |
| % Margin | -111.5% | -1,797.8% | -1,798.8% | 27.8% |
| Net Income | -$0 | -$0 | -$0 | $0 |
| % Margin | -111.5% | -348.4% | -1,764.2% | 29.3% |
| EPS Diluted | -0.3 | -0.11 | -0.56 | 0.21 |
| % Growth | -172.7% | 80.4% | -366.7% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | $0 |
| Capital Expenditures | $0 | $0 | $0 | $0 |
| Free Cash Flow | -$0 | -$0 | -$0 | $0 |